Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Restructuring Costs: 2024-2025

Historic Restructuring Costs for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to $8.6 million.

  • Monte Rosa Therapeutics' Restructuring Costs rose 15.01% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year change of. This contributed to the annual value of $29.6 million for FY2024, which is 8.55% up from last year.
  • Monte Rosa Therapeutics' Restructuring Costs amounted to $8.6 million in Q3 2025, which was up 9.22% from $7.8 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Restructuring Costs ranged from a high of $8.6 million in Q3 2025 and a low of $6.8 million during Q1 2024.
  • In the last 2 years, Monte Rosa Therapeutics' Restructuring Costs had a median value of $7.7 million in 2024 and averaged $7.8 million.
  • Data for Monte Rosa Therapeutics' Restructuring Costs shows a peak YoY grew of 20.86% (in 2025) over the last 5 years.
  • Monte Rosa Therapeutics' Restructuring Costs (Quarterly) stood at $7.7 million in 2024, then grew by 15.01% to $8.6 million in 2025.
  • Its Restructuring Costs stands at $8.6 million for Q3 2025, versus $7.8 million for Q2 2025 and $8.2 million for Q1 2025.